OncoCyte Corp reports results for the quarter ended in March - Earnings Summary

Insight Molecular Diagnostics

11/05/2022 22:45

* OncoCyte Corp  OCX.OQ  reported a quarterly adjusted loss
of 11
cents​​ per share for the quarter ended in March. The mean
expectation of seven analysts for the quarter was for a loss
of 12 cents per share.
    * Revenue rose 26.8% to $1.43 million from a year ago; 
analysts
expected $2.24 million. 
    * OncoCyte Corp's reported EPS for the quarter was a loss
of 11
cents​.
    * The mean earnings estimate of analysts had risen by
about 4.9%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * OncoCyte Corp shares had fallen by 22.1% this quarter and
lost 46.5% so far this year.
    * The company reported a quarterly loss of $10.29 million.
    * Wall Street's median 12-month price target for OncoCyte
Corp is
$4.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 11 at 09:45 p.m.  ​All
figures in US dollars unless otherwise stated